title: Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients.
abstract: OBJECTIVE
  To assess the prevalence of chronic hepatitis C virus (HCV) infection with persistently normal alanine aminotransferase (ALT) levels in HIV-1-infected patients, together with its clinical, biological and histological characteristics and predictive factors.
  
  
  METHODS
  We retrospectively studied all HCV/HIV-coinfected patients treated in our Infectious Diseases Department, for whom data on both HIV and HCV infection were available. We compared the demographic characteristics and parameters of HIV and HCV infection between cases, defined by persistently normal ALT levels (<45 IU/L) and detectable serum HCV-RNA (determined by PCR), and controls with high ALT levels and HCV PCR positivity during the previous 3 years.
  
  
  RESULTS
  Among the 815 HIV-infected patients assessed for this study, 179 (22%) were HCV-coinfected, of whom 155 were eligible for this analysis. Of these 155 HCV-coinfected patients, 137 (88%) were HCV-PCR-positive, of whom 39 (28.5%) had persistently normal ALT levels (cases) and 98 (71.5%) had high ALT levels (controls). Relative to controls, cases had a significantly lower fibrosis score and a lower fibrosis progression rate (2.2 vs. 1.3, P=0.004; 0.3 vs. 0.2, P=0.006, respectively). Three factors associated with persistently normal ALT levels were identified, namely: HBsAg negativity (P=0.003), HCV genotype 4 (P=0.01) and female sex (P=0.05).
  
  
  CONCLUSIONS
  Persistently normal ALT levels may be considered as a marker of slow HCV disease progression in HIV-coinfected patients, with significantly less severe hepatic lesions.
authors.affiliation: Division of Infectious Diseases, University Hospital of Saint-Antoine, Assistance Publique-Hôpitaux de Paris, 184 rue du faubourg Saint-Antoine, 75012 Paris, France. laurent.fonquernie@sat.ap-hop-paris.fr
authors.forename: L
authors.initials: L
authors.lastname: Fonquernie
authors.forename: L
authors.initials: L
authors.lastname: Serfaty
authors.forename: A
authors.initials: A
authors.lastname: Charrois
authors.forename: D
authors.initials: D
authors.lastname: Wendum
authors.forename: B
authors.initials: B
authors.lastname: Lefebvre
authors.forename: P M
authors.initials: PM
authors.lastname: Girard
authors.forename: J L
authors.initials: JL
authors.lastname: Meynard
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003430:Cross-Sectional Studies; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000201:enzymology / Q000473:pathology; D015497:HIV-1; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies
chemical_list: D012367:RNA, Viral; D000410:Alanine Transaminase